These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17339074)

  • 1. The extent of lymph node dissection in patients with localised prostate cancer: debate continues.
    Türkeri L
    Eur Urol; 2007 Jun; 51(6):1472-4. PubMed ID: 17339074
    [No Abstract]   [Full Text] [Related]  

  • 2. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients.
    Weckermann D; Dorn R; Trefz M; Wagner T; Wawroschek F; Harzmann R
    J Urol; 2007 Mar; 177(3):916-20. PubMed ID: 17296375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results.
    Maffezzini M
    J Urol; 2005 Sep; 174(3):1151-2; author reply 1152. PubMed ID: 16094087
    [No Abstract]   [Full Text] [Related]  

  • 4. Radioisotope guided sentinel lymph node dissection in patients with localized prostate cancer: results of the first 100 cases.
    Bastide C; Brenot-Rossi I; Garcia S; Rossi D
    Eur J Surg Oncol; 2009 Jul; 35(7):751-6. PubMed ID: 18538526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical importance of lymph node density in predicting outcome of prostate cancer patients.
    Cai T; Nesi G; Tinacci G; Giubilei G; Gavazzi A; Mondaini N; Zini E; Bartoletti R
    J Surg Res; 2011 May; 167(2):267-72. PubMed ID: 19783007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years.
    Schostak M; Krause H; Miller K; Schrader M; Kempkensteffen C; Kollermann J
    BJU Int; 2007 Jun; 99(6):1409-14. PubMed ID: 17428244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology insight: radioguided sentinel lymph node dissection in the staging of prostate cancer.
    Beri A; Janetschek G
    Nat Clin Pract Urol; 2006 Nov; 3(11):602-10. PubMed ID: 17088928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliability of preoperative diagnostics and location of lymph node metastases in presumed unilateral prostate cancer.
    Weckermann D; Holl G; Dorn R; Wagner T; Harzmann R
    BJU Int; 2007 May; 99(5):1036-40. PubMed ID: 17437437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The case against extended lymph-node dissection for prostate cancer.
    Huland H
    Nat Clin Pract Urol; 2006 Sep; 3(9):456-7. PubMed ID: 16964181
    [No Abstract]   [Full Text] [Related]  

  • 11. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.
    Boormans JL; Wildhagen MF; Bangma CH; Verhagen PC; van Leenders GJ
    BJU Int; 2008 Dec; 102(11):1589-93. PubMed ID: 18710447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is radiotherapy useful in node-positive prostate cancer patients after radical prostatectomy?
    Van Poppel H
    Eur Urol; 2009 May; 55(5):1012-3. PubMed ID: 19261377
    [No Abstract]   [Full Text] [Related]  

  • 13. An extended pelvic lymph-node dissection should be performed in most patients if radical prostatectomy is truly indicated.
    Burkhard FC; Schumacher MC; Studer UE
    Nat Clin Pract Urol; 2006 Sep; 3(9):454-5. PubMed ID: 16964180
    [No Abstract]   [Full Text] [Related]  

  • 14. Current status of lymph node-positive prostate cancer: Incidence and predictors of outcome.
    Swanson GP; Thompson IM; Basler J
    Cancer; 2006 Aug; 107(3):439-50. PubMed ID: 16795064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substaging pathologically organ confined (pT2) prostate cancer: an exercise in futility?
    van der Kwast TH
    Eur Urol; 2006 Feb; 49(2):209-11. PubMed ID: 16417961
    [No Abstract]   [Full Text] [Related]  

  • 16. [Sentinel lymph node dissection in prostate cancer. Experience after more than 800 interventions].
    Weckermann D; Hamm M; Dorn R; Wagner T; Wawroschek F; Harzmann R
    Urologe A; 2006 Jun; 45(6):723-7. PubMed ID: 16586052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 18. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
    D'Amico AV; Chen MH
    J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
    Stenman UH
    Eur Urol; 2007 Oct; 52(4):1074-5. PubMed ID: 17383813
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Alberto Briganti, Umberto Capitanio, Felix K.-H. Chun, et al. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol 2008;54:794-804.
    Cai T; Nesi G; Bartoletti R
    Eur Urol; 2009 Feb; 55(2):e32-3; author reply e34-5. PubMed ID: 18760527
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.